Published
Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms
No abstract availability was recorded for this entry.
No abstract availability was recorded for this entry.
0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.
No close related records were found yet.